Oncolytics Biotech names chief medical officer
Wednesday, July 6, 2011
Oncolytics Biotech has named George M. Gill, M.D., chief medical officer.
He had been senior vice president of clinical safety and regulatory affairs and an officer of Oncolytics since 2002.
“Dr. Gill has an outstanding track record, having supported the advancement of more than 20 products—including 11 anti-cancer agents—through the clinical research and regulatory approval process in the United States, Canada and Europe,” said Dr. Brad Thompson, president and CEO of Oncolytics.
Previously he was vice president of clinical research and medical affairs at Ligand Pharmaceuticals; senior director and head of U.S. clinical and medical affairs for ICI Pharmaceuticals and vice president and head of worldwide regulatory affairs for Bristol-Myers.